Shorter radiation course as effective as standard therapy for prostate cancer recurrence
A shorter, five-week course of radiation treatment that delivers higher doses of radiation in fewer sessions, known as hypofractionation, appears to be just as effective and as safe in reducing the risk of prostate cancer from returning as standard radiation therapy, yet is delivered in two-and-a-half weeks less time, according to interim results of a randomized study presented November 4, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO). "The study shows that hypofractionated radiation could potentially be used in place of standard radiation therapy for intermediate and high risk prostate cancer patients, but the results are still preliminary," Alan Pollack, M.D., lead author of the study and a radiation oncologist at the University of Miami Miller School of Medicine in Miami, Fla., said. "We are excited about this research because the shorter course of treatment is more convenient, would reduce health care costs and appears just as effective."
Patients in the study received a special type of external beam radiation called intensity modulated radiation therapy, or IMRT, that allows radiation to be more exactly shaped to fit the prostate. Using IMRT, the amount of radiation received by healthy tissues near the tumor are reduced. This has allowed the investigators to give higher doses per day without increasing toxicity significantly.
The study involved 303 men with intermediate and high risk prostate cancer who were randomized to receive hypofractionated IMRT for 26 treatments (five weeks of daily radiation therapy) or standard IMRT for 38 treatments (seven-and-a-half weeks of daily treatments) to the prostate and surrounding area. High-risk patients also received treatment to the pelvic lymph nodes.
In addition to radiation treatment, 34 of the 200 intermediate risk patients received short-term hormone therapy for a median of four months, while 102 of 103 high risk patients in the hypofractionated group received long-term hormone therapy for 25 months.
The study shows that 39 months after treatment, there is no significant difference in cancer recurrence between patients who underwent hypofractionated IMRT (14 percent) and standard IMRT (19 percent). There is also no difference in genitourinary and gastrointestinal side effects between the two groups.
"Although these are significant findings, longer follow-up is needed and a final analysis is planned for 2011," Dr. Pollack said. "Other clinical trials are exploring hypofractionation and I encourage men with prostate cancer interested in shorter treatments to talk to their radiation oncologist about joining a study."
Source: American Society for Radiation Oncology
Articles on the same topic
- Time between treatment and PSA recurrence predicts death from prostate cancerWed, 4 Nov 2009, 20:09:57 UTC
- Radiation therapy after lumpectomy for breast cancer can be safely reduced to 4 weeksWed, 4 Nov 2009, 18:11:33 UTC
- 3-week course of breast radiation may be as effective as conventional 5- to 7-week course for early breast cancersWed, 4 Nov 2009, 18:11:32 UTC
- Does race, income predict prostate cancer outcome?Wed, 4 Nov 2009, 17:31:18 UTC
- Cancer patients want honesty, compassion from their oncologistWed, 4 Nov 2009, 17:31:15 UTC
- Shorter radiation course stops cancer growth in high-risk prostate cancer patientsTue, 3 Nov 2009, 18:26:31 UTC
- Radiation therapy technique successfully treats pain in patients with advanced cancerTue, 3 Nov 2009, 16:08:59 UTC
- PET imaging before radiation not ideal for determining boost radiation dosesTue, 3 Nov 2009, 15:46:33 UTC
- Obesity significantly increases side effects of stereotactic body radiation therapy in lung cancer patientsMon, 2 Nov 2009, 18:24:29 UTC
- Proton therapy is well-tolerated in prostate cancer patientsMon, 2 Nov 2009, 17:59:49 UTC
- Stereotactic radiotherapy stops lung cancer from growing in frail patientsMon, 2 Nov 2009, 17:44:13 UTC
- Stereotactic radiotherapy stops lung cancer from growing in frail patientsMon, 2 Nov 2009, 17:44:11 UTC
- Stereotactic radiotherapy offers noninvasive, effective treatment for lung cancer patientsMon, 2 Nov 2009, 17:44:10 UTC
- Adding proton therapy 'boost' to X-ray radiation therapy reduces prostate cancer recurrencesMon, 2 Nov 2009, 17:39:33 UTC
- Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancerMon, 2 Nov 2009, 17:15:37 UTC
- Preventative brain radiation for lung cancer patients: Benefits and risksMon, 2 Nov 2009, 16:51:41 UTC
- Undetectable PSA after radiation is possible and predicts good patient outcomesMon, 2 Nov 2009, 16:33:07 UTC
- Additional, specialized radiation not necessary for some women after mastectomyMon, 2 Nov 2009, 16:33:05 UTC
- Real benefits vs. risks of preventative brain radiation for nonsmall cell lung cancer patientsMon, 2 Nov 2009, 16:33:04 UTC
- Radiation after surgery reduces chance of melanoma returningMon, 2 Nov 2009, 16:33:03 UTC
- Short-term hormone therapy added to radiation increases survival for medium-risk, but not low-risk, prostate cancer patientsMon, 2 Nov 2009, 16:33:00 UTC
Other sources
- Irradiated cancers stay downfrom Science AlertThu, 5 Nov 2009, 8:14:23 UTC
- Radiation therapy after lumpectomy for breast cancer can be safely reduced to 4 weeksfrom PhysorgWed, 4 Nov 2009, 21:28:05 UTC
- Cancer patients want honesty, compassion from their oncologistfrom PhysorgWed, 4 Nov 2009, 19:14:06 UTC
- Radiation therapy technique successfully treats pain in patients with advanced cancerfrom Science BlogTue, 3 Nov 2009, 21:07:19 UTC
- PET imaging before radiation not ideal for determining boost radiation dosesfrom PhysorgTue, 3 Nov 2009, 19:56:11 UTC
- Radiation Therapy Technique Successfully Treats Pain In Patients With Advanced Cancerfrom Science DailyTue, 3 Nov 2009, 17:21:13 UTC
- Radiation therapy technique successfully treats pain in patients with advanced cancerfrom PhysorgTue, 3 Nov 2009, 16:35:53 UTC
- Additional, specialized radiation not necessary for some women after mastectomyfrom PhysorgTue, 3 Nov 2009, 7:56:07 UTC
- Adding proton therapy 'boost' to X-ray radiation therapy reduces prostate cancer recurrencesfrom PhysorgTue, 3 Nov 2009, 4:56:07 UTC
- Proton Therapy Is Well-tolerated In Prostate Cancer Patientsfrom Science DailyTue, 3 Nov 2009, 4:14:07 UTC
- Stereotactic radiotherapy stops lung cancer from growing in frail patientsfrom PhysorgTue, 3 Nov 2009, 3:28:16 UTC
- Preventative brain radiation for lung cancer patients: Benefits and risksfrom PhysorgTue, 3 Nov 2009, 3:28:14 UTC
- Proton therapy is well-tolerated in prostate cancer patientsfrom PhysorgTue, 3 Nov 2009, 1:14:18 UTC
- Undetectable PSA after radiation is possible and predicts good patient outcomesfrom PhysorgTue, 3 Nov 2009, 0:07:19 UTC
- Radiation after surgery reduces chance of melanoma returningfrom PhysorgMon, 2 Nov 2009, 22:56:16 UTC
- Obesity significantly increases side effects of stereotactic body radiation therapy in lung cancer patientsfrom PhysorgMon, 2 Nov 2009, 21:49:15 UTC
- Preventative brain radiation for lung cancer patients: Benefits and risksfrom Science BlogMon, 2 Nov 2009, 18:49:09 UTC
- Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancerfrom PhysorgMon, 2 Nov 2009, 17:42:15 UTC
- Stereotactic Radiotherapy Offers Noninvasive, Effective Treatment for Frail Patients with Early-stage Lung Cancerfrom Newswise - ScinewsMon, 2 Nov 2009, 17:42:07 UTC
- Undetectable PSA After Radiation Is Possible And Predicts Good Patient Outcomesfrom Science DailyMon, 2 Nov 2009, 17:21:30 UTC
- Radiation After Surgery Reduces Chance Of Melanoma Returningfrom Science DailyMon, 2 Nov 2009, 16:28:58 UTC